# Tesamorelin

Tesamorelin has 21 registered human trials. It is marketed for 3 different uses.

**In short**

- 21 registered human trials exist for Tesamorelin.
- Tesamorelin is FDA-approved — FDA-approved for HIV-associated lipodystrophy..
- What has actually been studied: lipodystrophy, hiv infections, metabolic associated steatotic liver disease.
- Last checked against ClinicalTrials.gov on 2026-07-27.

## What it is sold for

- Visceral fat loss
- Anti-aging
- Cognition

## What has actually been tested

- Lipodystrophy
- HIV Infections
- Metabolic Associated Steatotic Liver Disease
- Nonalcoholic Steatohepatitis
- Hepatic Steatosis
- Mild Cognitive Impairment
- Abdominal Obesity
- Growth Hormone Deficiency
- Type 2 Diabetes
- HIV Lipodystrophy Syndrome
- Body Composition
- Healthy Volunteers
- Aging
- Peripheral Nerve Injuries
- Diabetic Retinopathy
- HIV
- Chronic Obstructive Pulmonary Disease (COPD)
- Non-Alcoholic Fatty Liver Disease
- Obesity
- Obesity, Abdominal
- Liver Fat
- Fatty Liver
- HIV Lipodystrophy
- Human Immunodeficiency Virus (HIV)
- Nonalcoholic Fatty Liver Disease (NAFLD)
- Nonalcoholic Steatohepatitis (NASH)
- HIV-1-infection
- Frailty
- Impaired Physical Function
- Sleep Disorder
- Traumatic Brain Injury

## Every trial on record

| Trial ID | Title | Condition | Phase | Status | Enrolled |
|---|---|---|---|---|---|
| [NCT00608023](https://clinicaltrials.gov/study/NCT00608023) | TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy | Lipodystrophy, HIV Infections | Phase 3 | COMPLETED | 263 |
| [NCT07481734](https://clinicaltrials.gov/study/NCT07481734) | Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study) | Metabolic Associated Steatotic Liver Disease, Nonalcoholic Steatohepatitis | Phase 2 | RECRUITING | 120 |
| [NCT02553603](https://clinicaltrials.gov/study/NCT02553603) | The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment | Mild Cognitive Impairment | Phase 1 | COMPLETED | 22 |
| [NCT00675506](https://clinicaltrials.gov/study/NCT00675506) | Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese | Abdominal Obesity, Growth Hormone Deficiency | Phase 2 | COMPLETED | 60 |
| [NCT01264497](https://clinicaltrials.gov/study/NCT01264497) | Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes | Type 2 Diabetes | Phase 2 | COMPLETED | 55 |
| [NCT03226821](https://clinicaltrials.gov/study/NCT03226821) | Body Composition and Adipose Tissue in HIV | HIV Lipodystrophy Syndrome, Growth Hormone Deficiency | Phase 4 | TERMINATED | 6 |
| [NCT00850564](https://clinicaltrials.gov/study/NCT00850564) | Effect of Short Term Growth Hormone Releasing Hormone in Healthy Men | Healthy Volunteers | Not phased | COMPLETED | 15 |
| [NCT00257712](https://clinicaltrials.gov/study/NCT00257712) | SMART: Somatotrophics, Memory, and Aging Research Trial | Aging, Mild Cognitive Impairment | Phase 2 | COMPLETED | 151 |
| [NCT03150511](https://clinicaltrials.gov/study/NCT03150511) | Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury | Peripheral Nerve Injuries | Phase 2 | RECRUITING | 36 |
| [NCT01591902](https://clinicaltrials.gov/study/NCT01591902) | Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® | Diabetic Retinopathy, HIV | Phase 4 | TERMINATED | 129 |
| [NCT02012556](https://clinicaltrials.gov/study/NCT02012556) | Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients | HIV | Phase 1 | COMPLETED | 18 |
| [NCT01388920](https://clinicaltrials.gov/study/NCT01388920) | Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting | Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | TERMINATED | 3 |
| [NCT03375788](https://clinicaltrials.gov/study/NCT03375788) | Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk | Non-Alcoholic Fatty Liver Disease, Obesity | Phase 2 | COMPLETED | 51 |
| [NCT00123253](https://clinicaltrials.gov/study/NCT00123253) | TH9507 in Patients With HIV-Associated Lipodystrophy | HIV Infections, Lipodystrophy | Phase 3 | COMPLETED | 412 |
| [NCT01263717](https://clinicaltrials.gov/study/NCT01263717) | Effects of Growth Hormone Releasing Hormone in HIV | HIV, HIV Lipodystrophy | Not phased | COMPLETED | 54 |
| [NCT01632592](https://clinicaltrials.gov/study/NCT01632592) | Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue | Abdominal Obesity | Not phased | WITHDRAWN | 0 |
| [NCT00795210](https://clinicaltrials.gov/study/NCT00795210) | Effects of Short-term Growth Hormone in HIV-infected Patients | HIV Lipodystrophy | Not phased | COMPLETED | 25 |
| [NCT02196831](https://clinicaltrials.gov/study/NCT02196831) | Tesamorelin Effects on Liver Fat and Histology in HIV | Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD) | Not phased | COMPLETED | 61 |
| [NCT06554717](https://clinicaltrials.gov/study/NCT06554717) | Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV | HIV-1-infection, Frailty | Phase 2 | RECRUITING | 100 |
| [NCT02572323](https://clinicaltrials.gov/study/NCT02572323) | Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons | Mild Cognitive Impairment | Phase 2 | COMPLETED | 73 |
| [NCT02931474](https://clinicaltrials.gov/study/NCT02931474) | Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia | Sleep Disorder, Traumatic Brain Injury | Phase 2 | WITHDRAWN | 0 |

## Common questions

**How many human trials does Tesamorelin have?**
21, each listed above with a link to its original record.

**Is Tesamorelin FDA approved?**
Yes — FDA-approved for HIV-associated lipodystrophy.

**Where does this data come from?**
ClinicalTrials.gov. We count interventional human studies only. Every trial
links to its original record.

---

*Automated aggregation from public registries. Not medical advice. No physician
has reviewed this page. Source: https://www.whatsactuallyknown.com/compounds/tesamorelin*